SG
ALXN

Societe Generale’s Alexion Pharmaceuticals ALXN Stock Holding History

Societe Generale’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$1.5M Buy
+49,500
New +$7.02M 0.01% 1028

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Societe Generale's ALXN Position: Q2 2016 in Review

Societe Generale opened a new position in Alexion Pharmaceuticals (ALXN) in Q2 2016: 29,653 shares worth $3.46M. The stake represents 0.02% of the portfolio and ranks #531 among its holdings.

533 funds tracked by Wall St. Rank hold ALXN as of Q2 2016.

  • Societe Generale held 29,653 shares of Alexion Pharmaceuticals worth $3.46M as of Q2 2016.
  • Alexion Pharmaceuticals was a new Societe Generale position in Q2 2016.
  • Alexion Pharmaceuticals made up 0.02% of Societe Generale's portfolio in Q2 2016, its #531 holding.
  • 533 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.